The trading price of Virax Biolabs Group Ltd (NASDAQ:VRAX) closed higher on current market day and closing at $2.87, 1.06% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $2.55 and $3.02. In examining the 52-week price action we see that the stock hit a 52-week high of $9.00 and a 52-week low of $0.60. Over the past month, the stock has gained 34.74% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Virax Biolabs Group Ltd, whose market valuation is $12.46 million at the time of this writing, is expected to release its quarterly earnings report in October. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 0 per share this quarter, however they have predicted annual earnings per share of 0 for current year and 0 for next year.
From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 10k.
On the technical side, indicators suggest VRAX has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
A quick review shows that VRAX’s price is currently -30.94% off the SMA20 and 19.51% off the SMA50. The RSI metric on the 14-day chart is currently showing 46.54, and weekly volatility stands at 17.42%. When measured over the past 30 days, the indicator reaches 29.11%. Virax Biolabs Group Ltd (NASDAQ:VRAX)’s beta value is currently sitting at 2.16, while the Average True Range indicator is currently displaying 0.80.
To see how Virax Biolabs Group Ltd stock has been performing in comparison to its peers in the industry, here are the numbers: VRAX stock’s performance was 1.06% in the latest trading, and -22.58% in the past year.
An evaluation of the daily trading volume of Virax Biolabs Group Ltd (NASDAQ:VRAX) indicates that the 3-month average is 4.59 million. However, this figure has increased over the past 10 days to an average of 2.49.
Currently, records show that 4.34 million of the company’s shares remain outstanding. The insiders hold 6.63% of outstanding shares, whereas institutions hold 1.63%. The stats also highlight that short interest as of 2024-08-30, stood at 0.63 million shares, resulting in a short ratio of 0.06 at that time. From this, we can conclude that short interest is 1560.00 of the company’s total outstanding shares. It is noteworthy that short shares in August were up slightly from the previous month’s figure, which was 18866.0. However, since the stock’s price has seen 96.58% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
